Infants at Risk for Aluminum Toxicity with Unapproved Potassium Phosphates Drug Product

The FDA is warning healthcare professionals and pharmacies to avoid using Hospira’s unapproved potassium phosphates product in pediatric patients due to the potential for aluminum exposure up to twice the FDA-recommended limit for parenteral nutrition, which is unsafe. The FDA provides recommendations for the use of FDA-approved potassium phosphates injection products with acceptable aluminum content levels. Read the full FDA warning here.